Rep. Gilbert Ray Cisneros Jr. (D-CA) Buys BSX Stock
Rep. Cisneros adds to his portfolio with a purchase of Boston Scientific shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Gilbert Ray Cisneros Jr. (D-CA) bought between $1,001 and $15,000 of Boston Scientific Corporation ($BSX) stock on June 5, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed July 2, 2026.
Since the trade, $BSX is down 3.4% after 1 week, down 8.1% after 1 month and down 8.6% to date (from the $48.55 close on Jun 5, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Ray Cisneros Jr. (D)
- Status:
- Member — House
- Party:
- Democrat
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jul 2, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Boston Scientific Corporation ($BSX) | Buy | Jun 5, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
BSX
Boston Scientific Corporation
Key Points
- Rep. Gilbert Ray Cisneros Jr. bought Boston Scientific shares valued between $1,001 and $15,000 on June 5, 2026.
- Boston Scientific's stock closed at $44.12 on the day of the transaction, which is near its 52-week low of $41.39.
- The company operates in the healthcare sector, specifically in medical devices, with a market cap of about $63.97 billion.
Get $BSX trade alerts by text
We text you when insiders, Congress or big funds trade $BSX. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Boston Scientific Corporation alert may contain errors. Disclosures
Rep. Gilbert Ray Cisneros Jr., a Democrat from California's 31st district, purchased shares of Boston Scientific Corporation (NYSE: BSX) on June 5, 2026. The transaction, valued between $1,001 and $15,000, was reported on July 2, 2026. On the day of the purchase, Boston Scientific's shares closed at $44.12.
Gilbert Ray Cisneros Jr. vs. the S&P 500
Hypothetical returns from Gilbert Ray Cisneros Jr.'s disclosed trades, not real profit or advice. How we model this.
Inside Gilbert Ray Cisneros Jr.'s Trade
Cisneros' recent buy adds to his portfolio amidst a series of transactions, including sales of shares in other companies on the same day. This move may reflect his ongoing interest in the healthcare sector, where Boston Scientific operates.
Other Institutional Activity in Boston Scientific
Blackrock Inc. trimmed its stake in Boston Scientific by 2,135,425 shares, bringing its total to about 129.7 million shares, valued at approximately $5.73 billion. Vanguard Capital Management LLC increased its holdings by 674,889 shares, now owning about 97.1 million shares worth about $4.29 billion. State Street Corporation added 2,121,285 shares, ending with 70.1 million shares valued at around $3.10 billion. Primecap Management Company grew its stake significantly by 17,991,834 shares, totaling about 50.5 million shares worth about $2.23 billion. In contrast, FMR, LLC reduced its position by 28,526,236 shares, now holding about 45.7 million shares valued at approximately $2.02 billion.
Boston Scientific Corporation Stock Up 2.6%
Boston Scientific's shares are currently trading near their 52-week low of $41.39, which could indicate a buying opportunity for some investors. The stock's 50-day moving average is $46.18, suggesting it has struggled to maintain higher prices recently.
Recent Earnings
In its latest earnings report, Boston Scientific posted revenue of approximately $20.99 billion, reflecting a growth rate of 7.5%. The company reported earnings per share (EPS) of $2.47 and a net margin of about 17.5%. The next earnings report is scheduled for October 28, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
12 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
-
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 12 target cuts.
-
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.
Earnings Call Summary
Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.
Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Boston Scientific Corporation
Several insiders have been active recently. CEO Michael F. Mahoney bought 186,240 shares at an average price of $48.33 on August 3, 2026, totaling about $9 million. Director Susan E. Morano purchased 2,040 shares at $49.22 on August 25, 2026, valued at around $100,408. Another director, David C. Habiger, bought 2,100 shares at an average price of $47.59 on August 5, 2026, totaling about $99,937.
Analysts Set New Price Targets
Analysts have mixed views on Boston Scientific. On October 14, 2026, Truist Securities maintained a Buy rating with a price target of $51.00, down from a prior target of $57.00. Barclays initiated coverage with an Equal-Weight rating and a target of $48.00 on October 7, 2026. Citigroup and Wells Fargo both maintained Neutral and Equal-Weight ratings, respectively, with targets of $48.00.
About Boston Scientific
Boston Scientific Corporation develops and sells medical devices for various medical specialties around the world. The company operates mainly in two areas: MedSurg and Cardiovascular. With a strong market presence and a focus on innovation, Boston Scientific continues to be a key player in the healthcare industry.
Bottom Line
Investors will want to watch Boston Scientific's upcoming earnings report on October 28, 2026, for insights into its performance. The recent transactions by Rep. Cisneros and other insiders may provide additional context for the company's current standing in the market. Remember that the 13F filing reflects past holdings and may not represent current positions.
Related Filing Alerts
Source: Gilbert Ray Cisneros Jr.'s STOCK Act disclosure on $BSX (Jun 5, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts